北交所及港交所(00388.HK)簽合作備忘錄 推進「北+H」上市安排
北交所與港交所(00388.HK)簽署合作備忘錄,聯合宣布京港兩所將推出「北+H」兩地上市安排。
北交所總經理隋強表示,有關安排為推進資本市場制度型開放、持續深化北交所改革、服務市場需求的重要舉措,將進一步拓寬內地和香港「A+H」模式的惠及面,促進京港兩地資本市場形成合力,便利更多企業借助兩地市場加速發展。
隋強指,根據各方反映,業界普遍希望北交所積極探索國際化業務,有北交所上市公司提出開啟赴港二次上市,以豐富融資渠道、便利開展國際業務;亦有在港上市公司提出明確「北歸」上市方式,分享北交所發展紅利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.